Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
BCA101 is a bifunctional antibody that targets both EGFR and TGFB and leads to inhibition of downstream signaling, which may lead to inhibition of tumor cell proliferation and activation of anti-tumor immune response (PMID: 37074042).
|DrugClasses||EGFR Antibody 52 TGFB (Pan) Antibody 5|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|BCA101 + Pembrolizumab||BCA101 Pembrolizumab||0||1|
|BCA101 + unspecified PD-1 antibody||BCA101 unspecified PD-1 antibody||0||0|